• Agios posted Phase 2 topline data for tebapivat in sickle cell disease, citing no differentiated profile to justify continued development.
• Hemoglobin response met 43.8% at 2.5 mg, 47.1% at 5 mg, 29.4% at 7.5 mg; placebo was 33.3%.
• Mitapivat sickle cell sNDA remains under FDA Priority Review; PDUFA goal date is Nov. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210700PRIMZONEFULLFEED9765228) on July 21, 2026, and is solely responsible for the information contained therein.